HomeCompareABT vs MCO

ABT vs MCO: Dividend Comparison 2026

ABT yields 2.36% · MCO yields 0.89%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABT wins by $326.4K in total portfolio value
10 years
ABT
ABT
● Live price
2.36%
Share price
$101.89
Annual div
$2.40
5Y div CAGR
63.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$533.6K
Annual income
$328,772.04
Full ABT calculator →
MCO
MCO
● Live price
0.89%
Share price
$432.05
Annual div
$3.85
5Y div CAGR
74.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$207.2K
Annual income
$113,279.94
Full MCO calculator →

Portfolio growth — ABT vs MCO

📍 ABT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodABTMCO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ABT + MCO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ABT pays
MCO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ABT
Annual income on $10K today (after 15% tax)
$200.23/yr
After 10yr DRIP, annual income (after tax)
$279,456.23/yr
MCO
Annual income on $10K today (after 15% tax)
$75.74/yr
After 10yr DRIP, annual income (after tax)
$96,287.95/yr
At 15% tax rate, ABT beats the other by $183,168.29/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ABT + MCO for your $10,000?

ABT: 50%MCO: 50%
100% MCO50/50100% ABT
Portfolio after 10yr
$370.4K
Annual income
$221,025.99/yr
Blended yield
59.67%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABT right now

ABT
Analyst Ratings
30
Buy
10
Hold
Consensus: Buy
Price Target
$137.67
+35.1% upside vs current
Range: $120.00 — $158.00
Altman Z
4.9
Piotroski
6/9
MCO
Analyst Ratings
18
Buy
13
Hold
1
Sell
Consensus: Buy
Price Target
$543.08
+25.7% upside vs current
Range: $480.00 — $620.00
Altman Z
5.3
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ABT buys
0
MCO buys
0
No recent congressional trades found for ABT or MCO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricABTMCO
Forward yield2.36%0.89%
Annual dividend / share$2.40$3.85
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR63.2%74.8%
Portfolio after 10y$533.6K$207.2K
Annual income after 10y$328,772.04$113,279.94
Total dividends collected$492.4K$178.5K
Payment frequencyquarterlyquarterly
SectorHealthcareFinancials
Analyst consensusBuyBuy
Analyst price target$137.67$543.08

Year-by-year: ABT vs MCO ($10,000, DRIP)

YearABT PortfolioABT Income/yrMCO PortfolioMCO Income/yrGap
1← crossover$11,084$384.43$10,856$155.76+$228.00ABT
2$12,510$649.94$11,892$276.24+$618.00ABT
3$14,505$1,118.82$13,219$494.35+$1.3KABT
4$17,499$1,978.53$15,042$897.70+$2.5KABT
5$22,364$3,640.59$17,763$1,668.77+$4.6KABT
6$31,026$7,096.70$22,226$3,219.45+$8.8KABT
7$48,215$15,016.56$30,363$6,580.83+$17.9KABT
8$87,182$35,592.30$47,175$14,686.41+$40.0KABT
9$191,446$98,161.15$87,754$37,276.83+$103.7KABT
10$533,619$328,772.04$207,177$113,279.94+$326.4KABT

ABT vs MCO: Complete Analysis 2026

ABTHealthcare

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Full ABT Calculator →

MCOFinancials

Moody's Corporation operates as an integrated risk assessment firm worldwide. It operates in two segments, Moody's Investors Service and Moody's Analytics. The Moody's Investors Service segment publishes credit ratings and provides assessment services on various debt obligations, programs and facilities, and entities that issue such obligations, such as various corporate, financial institution, and governmental obligations, as well as and structured finance securities. This segment provides ratings in approximately 140 countries. Its ratings are disseminated through press releases to the public through electronic media, including the internet and real-time information systems used by securities traders and investors. This segment has rated approximately 5,000 non-financial corporates; 3,600 financial institutions; 16,000 public finance issuers; 145 sovereigns; 47 supranational institutions; 459 sub-sovereigns; and 1,000 infrastructure and project finance issuers, as well as 9,100 structured finance deals. The Moody's Analytics segment develops a range of products and services that support the risk management activities of institutional participants in financial markets; and offers subscription based research, data, and analytical products comprising credit ratings, credit research, quantitative credit scores and other analytical tools, economic research and forecasts, business intelligence and company information products, commercial real estate data and analytical tools, and on-line and classroom-based training services, as well as credentialing and certification services. It also offers offshore analytical and research services with learning solutions and certification programs; and software solutions, as well as related risk management services. The company was formerly known as Dun and Bradstreet Company and changed its name to Moody's Corporation in September 2000. Moody's Corporation was founded in 1900 and is headquartered in New York, New York.

Full MCO Calculator →
📬

Get this ABT vs MCO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ABT vs SCHDABT vs JEPIABT vs OABT vs KOABT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.